Free Trial
NASDAQ:FBIO

Fortress Biotech (FBIO) Stock Price, News & Analysis

Fortress Biotech logo
$1.99 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$1.98 -0.01 (-0.50%)
As of 06:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Fortress Biotech Stock (NASDAQ:FBIO)

Key Stats

Today's Range
$1.92
$2.02
50-Day Range
$1.65
$2.13
52-Week Range
$1.33
$2.89
Volume
188,501 shs
Average Volume
412,607 shs
Market Capitalization
$58.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00
Consensus Rating
Buy

Company Overview

Fortress Biotech Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
43rd Percentile Overall Score

FBIO MarketRank™: 

Fortress Biotech scored higher than 43% of companies evaluated by MarketBeat, and ranked 622nd out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Fortress Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Fortress Biotech has received no research coverage in the past 90 days.

  • Read more about Fortress Biotech's stock forecast and price target.
  • Earnings Growth

    Earnings for Fortress Biotech are expected to grow in the coming year, from ($3.28) to ($1.13) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Fortress Biotech is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Fortress Biotech is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Fortress Biotech's valuation and earnings.
  • Percentage of Shares Shorted

    15.57% of the float of Fortress Biotech has been sold short.
  • Short Interest Ratio / Days to Cover

    Fortress Biotech has a short interest ratio ("days to cover") of 15.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Fortress Biotech has recently decreased by 2.08%, indicating that investor sentiment is improving.
  • Dividend Yield

    Fortress Biotech does not currently pay a dividend.

  • Dividend Growth

    Fortress Biotech does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    15.57% of the float of Fortress Biotech has been sold short.
  • Short Interest Ratio / Days to Cover

    Fortress Biotech has a short interest ratio ("days to cover") of 15.4, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Fortress Biotech has recently decreased by 2.08%, indicating that investor sentiment is improving.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Fortress Biotech this week, compared to 1 article on an average week.
  • Search Interest

    6 people have searched for FBIO on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Fortress Biotech insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    27.90% of the stock of Fortress Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    96.51% of the stock of Fortress Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Fortress Biotech's insider trading history.
Receive FBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fortress Biotech and its competitors with MarketBeat's FREE daily newsletter.

FBIO Stock News Headlines

FBIO Fortress Biotech, Inc. - Seeking Alpha
The $7 company helping Nvidia build the world’s first trillion-dollar robot …
Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profitable trends in tech … well ahead of Wall Street. Like when he called Nvidia at a mere 80 cents a share. Or Bitcoin when it was trading for just $300. Throughout his illustrious career … Michael has given his followers almost 150 different chances to register triple-digit gains.
See More Headlines

FBIO Stock Analysis - Frequently Asked Questions

Fortress Biotech's stock was trading at $2.03 at the start of the year. Since then, FBIO shares have decreased by 2.0% and is now trading at $1.99.

Fortress Biotech, Inc. (NASDAQ:FBIO) posted its earnings results on Monday, March, 31st. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.79) by $0.53. The biopharmaceutical company earned $15.12 million during the quarter, compared to the consensus estimate of $16.30 million. Fortress Biotech had a negative net margin of 71.24% and a negative trailing twelve-month return on equity of 4,712.53%.
Read the conference call transcript
.

Fortress Biotech's stock reverse split on Tuesday, October 10th 2023.The 1-15 reverse split was announced on Monday, October 9th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Shares of FBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Fortress Biotech investors own include Plug Power (PLUG), FuelCell Energy (FCEL), Workhorse Group (WKHS), KALA BIO (KALA), Ovid Therapeutics (OVID), Lipocine (LPCN) and Comtech Telecommunications (CMTL).

Company Calendar

Last Earnings
3/31/2025
Today
7/10/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:FBIO
CIK
1429260
Employees
170
Year Founded
N/A

Price Target and Rating

High Price Target
$26.00
Low Price Target
$16.00
Potential Upside/Downside
+944.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.23)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$46 million
Net Margins
-71.24%
Pretax Margin
-183.81%
Return on Equity
-4,712.53%
Return on Assets
-27.67%

Debt

Debt-to-Equity Ratio
1.74
Current Ratio
1.72
Quick Ratio
1.55

Sales & Book Value

Annual Sales
$57.67 million
Price / Sales
1.03
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.06) per share
Price / Book
-33.50

Miscellaneous

Outstanding Shares
29,570,000
Free Float
21,320,000
Market Cap
$59.44 million
Optionable
Optionable
Beta
1.75

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:FBIO) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners